Amino Collective
VC Fund
Berlin, Germany
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Amino Collective invests in
Stages Amino Collective invests in
Countries Amino Collective invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.4M–$14M
- Pre-Seed
- $125k–$7.8M
- Series A
- $12M–$37M
Investment Focus
Industry
- Biotechnology 14 (30%)
- Health Care 13 (28%)
- Artificial Intelligence 10 (22%)
- Medical 7 (15%)
- Software 7 (15%)
Stage
- Seed 17 (37%)
- Series A 13 (28%)
- Pre-Seed 10 (22%)
- Series B 3 (7%)
- Funding Round 1 (2%)
Country
- United States 9 (20%)
- United Kingdom 7 (15%)
- Germany 5 (11%)
- Switzerland 2 (4%)
- Spain 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Manuel Grossmann
Founding Partner
|
Founding Partner | Total investments: 22 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tandem Health develops AI tools that support clinical documentation, coding, decision support, and follow-up across healthcare workflows. Its AI Medical Scribe captures conversations during patient visits and converts relevant information into structured clinical notes, referrals, summaries, and other documents for review. The platform alsoprovides suggested diagnosis and procedure codes and allows clinicians to edit documentation through voice commands. Tandem Health integrates with medical record, dental, pharmacy, and care-management systems, enabling approved notes and related documents to transfer directly into existing records. Its solutions support healthcare professionals across medical, nursing, physiotherapy, dental, mental health, social care, and veterinary settings. | $100M / Series B / Sep 14, 2026 | ||
| Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it. | $3.3M / Pre-Seed / Apr 22, 2026 | ||
| Modern Relay provides context graph for enterprise AI. | $2.9M / Seed / Apr 14, 2026 | ||
| Theorema.ai is an AI-powered startup that focuses on autonomous R&D agents for science-intensive industries, including innovative materials, biotech, pharmaceuticals, and chemicals. | $3.3M / Pre-Seed / Mar 27, 2026 | ||
| Rivia is a next-gen operating system for improved trial outcomes. They have personally endured the exact clinical trial challenges they are solving. | $15M / Series A / Mar 18, 2026 | ||
| Valinor Discovery uses machine learning to simulate drug performance and support data-driven drug development decisions. | $13M / Seed / Dec 10, 2025 | ||
| Portal Biotech is a biotechnology company specializing in advanced proteomics and metabolomics through single-molecule detection. | $37.1M / Series A / Jun 30, 2025 | ||
| Tandem Health develops AI tools that support clinical documentation, coding, decision support, and follow-up across healthcare workflows. Its AI Medical Scribe captures conversations during patient visits and converts relevant information into structured clinical notes, referrals, summaries, and other documents for review. The platform alsoprovides suggested diagnosis and procedure codes and allows clinicians to edit documentation through voice commands. Tandem Health integrates with medical record, dental, pharmacy, and care-management systems, enabling approved notes and related documents to transfer directly into existing records. Its solutions support healthcare professionals across medical, nursing, physiotherapy, dental, mental health, social care, and veterinary settings. | $50.2M / Series A / Jun 30, 2025 | ||
| With the use of Hedera Dx's liquid biopsy solution, hospital labs will be able to conduct clinically useful liquid biopsies on their own. This will greatly simplify tumor profiling. It is difficult to accomplish IVD compliance, privacy infrastructure, and validation, and even if these challenges are overcome, the current software workflows areinefficient to use and lack key capabilities.Hedera Dx was established on July 1, 2021 in Epalinges, Vaud. | $17M / Series A / May 27, 2025 | ||
| Inductive Bio provides the information, machine learning, tools, and know-how required to resolve ADMET issues. | $25M / Series A / May 07, 2025 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Amino Collective invest in?
Amino Collective invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 46 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Amino Collective's check size?
Amino Collective typically joins rounds of $2.4M–$14M at Seed, $125k–$7.8M at Pre-Seed and $12M–$37M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Amino Collective participates in.
How do I contact Amino Collective?
Public channels for Amino Collective include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Amino Collective?
The team at Amino Collective includes Manuel Grossmann (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
